FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569026522> ?p ?o ?g. }

• W2569026522 endingPage "S974" @default.
• W2569026522 startingPage "S973" @default.
• W2569026522 abstract "Molecular profiling of advanced non-small-cell lung cancer (NSCLC) is recommended according to patients’ histological and clinical features. Despite the existence of national guidelines, routine care is still heterogeneous. Aim of this observational study was to obtain prospectively a clinical practice picture of molecular testing and therapeutic choices in advanced NSCLC patients. Newly diagnosed metastatic or recurrent NSCLC patients enrolled in 38 Italian centers, from November 2014 to November 2015, have been included in the study. Baseline information were collected about molecular profiling performed and therapies. A total of 1787 patients were enrolled (64% males, 36% females; median age 67 years-old; 22% never smokers, 31% current smokers, 47% former smokers; 75% adenocarcinoma, and 73% with PS ECOG 0 or 1). The 73.9% of diagnosis was histological, while 26.1% was cytological. 1382 (77%) patients were tested for one or more molecular analysis during the history of disease, for a total of 3532 molecular tests. Only 405 patients did not receive any molecular test. 32.3% of patients presented a genetic alteration: EGFR mutation was reported in 17.8% of cases (319/1787), ALK translocation in 8.8% (82/926), KRAS mutation in 31.9% (154/482), MET amplifications in 15.8% (10/63), BRAF mutations in 3.7% (9/241), ROS1 translocation in 4% (11/269), HER2 mutation in 3.3% (3/89) of cases and FGFR alteration was found in 3 cases (only 15 tested). Considering patients younger than 45 years, never smokers and females, an EGFR mutation was detected in 25.4%, 43.5% and 30.6%, respectively. While 15.6%, 9.5% and 6.3% were ALK rearranged, respectively. For patients receiving an EGFR tyrosine-kinase inhibitor as first-line treatment, among those whose data are evaluable (79.2%), the median interval from diagnosis to first-line was 35 days. EGFR mutated patients received first-line erlotinib, gefitinib and afatinib in 9.4%, 39.1% and 33.8% of cases, respectively. At time of analysis, ALK-rearranged patients received an ALK inhibitor (crizotinib, alectinib or ceritinib) as first and/or second-line in 71.9% of cases. 29.3% of all patients received a maintenance therapy, mainly with pemetrexed (91.2% of cases). Routine molecular assessing is properly performed according to the national guidelines. A selection bias in including only those patients performing molecular tests, may explain the high proportion of patients with a molecular alteration. The low number of patients tested for ALK could be partially related to the impossibility to prescribe Crizotinib in first- line. In more than 70% of cases EGFR mutated patients received gefitinib or afatinib as first-line treatment." @default.
• W2569026522 created "2017-01-13" @default.
• W2569026522 creator A5001428569 @default.
• W2569026522 creator A5007382846 @default.
• W2569026522 creator A5007575010 @default.
• W2569026522 creator A5008166009 @default.
• W2569026522 creator A5010900232 @default.
• W2569026522 creator A5011655337 @default.
• W2569026522 creator A5012939000 @default.
• W2569026522 creator A5016711314 @default.
• W2569026522 creator A5017359826 @default.
• W2569026522 creator A5030465858 @default.
• W2569026522 creator A5032078755 @default.
• W2569026522 creator A5039259142 @default.
• W2569026522 creator A5040884103 @default.
• W2569026522 creator A5046559582 @default.
• W2569026522 creator A5051002285 @default.
• W2569026522 creator A5051378203 @default.
• W2569026522 creator A5052937372 @default.
• W2569026522 creator A5058643588 @default.
• W2569026522 creator A5064222874 @default.
• W2569026522 creator A5078987153 @default.
• W2569026522 creator A5080028696 @default.
• W2569026522 creator A5081676975 @default.
• W2569026522 creator A5088252056 @default.
• W2569026522 creator A5089315207 @default.
• W2569026522 creator A5091893637 @default.
• W2569026522 date "2017-01-01" @default.
• W2569026522 modified "2023-10-18" @default.
• W2569026522 title "P2.03b-063 Molecular Profiling in Advanced Non-Small-Cell Lung Cancer: Preliminary Data of an Italian Observational Prospective Study" @default.
• W2569026522 doi "https://doi.org/10.1016/j.jtho.2016.11.1344" @default.
• W2569026522 hasPublicationYear "2017" @default.
• W2569026522 type Work @default.
• W2569026522 sameAs 2569026522 @default.
• W2569026522 citedByCount "0" @default.
• W2569026522 crossrefType "journal-article" @default.
• W2569026522 hasAuthorship W2569026522A5001428569 @default.
• W2569026522 hasAuthorship W2569026522A5007382846 @default.
• W2569026522 hasAuthorship W2569026522A5007575010 @default.
• W2569026522 hasAuthorship W2569026522A5008166009 @default.
• W2569026522 hasAuthorship W2569026522A5010900232 @default.
• W2569026522 hasAuthorship W2569026522A5011655337 @default.
• W2569026522 hasAuthorship W2569026522A5012939000 @default.
• W2569026522 hasAuthorship W2569026522A5016711314 @default.
• W2569026522 hasAuthorship W2569026522A5017359826 @default.
• W2569026522 hasAuthorship W2569026522A5030465858 @default.
• W2569026522 hasAuthorship W2569026522A5032078755 @default.
• W2569026522 hasAuthorship W2569026522A5039259142 @default.
• W2569026522 hasAuthorship W2569026522A5040884103 @default.
• W2569026522 hasAuthorship W2569026522A5046559582 @default.
• W2569026522 hasAuthorship W2569026522A5051002285 @default.
• W2569026522 hasAuthorship W2569026522A5051378203 @default.
• W2569026522 hasAuthorship W2569026522A5052937372 @default.
• W2569026522 hasAuthorship W2569026522A5058643588 @default.
• W2569026522 hasAuthorship W2569026522A5064222874 @default.
• W2569026522 hasAuthorship W2569026522A5078987153 @default.
• W2569026522 hasAuthorship W2569026522A5080028696 @default.
• W2569026522 hasAuthorship W2569026522A5081676975 @default.
• W2569026522 hasAuthorship W2569026522A5088252056 @default.
• W2569026522 hasAuthorship W2569026522A5089315207 @default.
• W2569026522 hasAuthorship W2569026522A5091893637 @default.
• W2569026522 hasBestOaLocation W25690265221 @default.
• W2569026522 hasConcept C121608353 @default.
• W2569026522 hasConcept C126322002 @default.
• W2569026522 hasConcept C142724271 @default.
• W2569026522 hasConcept C143998085 @default.
• W2569026522 hasConcept C23131810 @default.
• W2569026522 hasConcept C2775999482 @default.
• W2569026522 hasConcept C2776256026 @default.
• W2569026522 hasConcept C2781182431 @default.
• W2569026522 hasConcept C2781187634 @default.
• W2569026522 hasConcept C526805850 @default.
• W2569026522 hasConcept C71924100 @default.
• W2569026522 hasConcept C90924648 @default.
• W2569026522 hasConceptScore W2569026522C121608353 @default.
• W2569026522 hasConceptScore W2569026522C126322002 @default.
• W2569026522 hasConceptScore W2569026522C142724271 @default.
• W2569026522 hasConceptScore W2569026522C143998085 @default.
• W2569026522 hasConceptScore W2569026522C23131810 @default.
• W2569026522 hasConceptScore W2569026522C2775999482 @default.
• W2569026522 hasConceptScore W2569026522C2776256026 @default.
• W2569026522 hasConceptScore W2569026522C2781182431 @default.
• W2569026522 hasConceptScore W2569026522C2781187634 @default.
• W2569026522 hasConceptScore W2569026522C526805850 @default.
• W2569026522 hasConceptScore W2569026522C71924100 @default.
• W2569026522 hasConceptScore W2569026522C90924648 @default.
• W2569026522 hasIssue "1" @default.
• W2569026522 hasLocation W25690265221 @default.
• W2569026522 hasOpenAccess W2569026522 @default.
• W2569026522 hasPrimaryLocation W25690265221 @default.
• W2569026522 hasRelatedWork W1983690566 @default.
• W2569026522 hasRelatedWork W2128113587 @default.
• W2569026522 hasRelatedWork W2481242335 @default.
• W2569026522 hasRelatedWork W2656042639 @default.
• W2569026522 hasRelatedWork W2763698474 @default.
• W2569026522 hasRelatedWork W2895249728 @default.
• W2569026522 hasRelatedWork W3006198547 @default.
• W2569026522 hasRelatedWork W3123227589 @default.

• next